RARA and acute myeloid leukemia: The profile of the ZBTB16‐RARA+ AML was “intermediate” between APL and other AMLs, including recurrent mutations in AMLs, such as those in TET2, RUNX1 and CSF3R, and mutations rarely reported in APL, such as ARID1A. 15Mutations in ARID1A, belonging to the SWI/SNF chromatin remodeling complexes, have been previously described in hematological malignancies, including chronic lymphocytic leukemia and hairy cell leukemia, and in solid cancers.15, 16, 17, 18, 19, 20